SU-E-T-486: In Vivo Skin Dosimetry Using the Exradin W1 Plastic Scintillation Detector for Passively Scattered Proton Beam Therapy

Authors

  • Alsanea F,

    1. UT MD Anderson Cancer Center, Houston, TX
    2. M.D. Anderson Cancer Center, Houston, TX
    3. UT MD Anderson Cancer Center, Houston, TX
    4. UT MD Anderson Cancer Center, Houston, TX
    5. UT MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author
  • Wootton L,

    1. UT MD Anderson Cancer Center, Houston, TX
    2. M.D. Anderson Cancer Center, Houston, TX
    3. UT MD Anderson Cancer Center, Houston, TX
    4. UT MD Anderson Cancer Center, Houston, TX
    5. UT MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author
  • Kudchadker R,

    1. UT MD Anderson Cancer Center, Houston, TX
    2. M.D. Anderson Cancer Center, Houston, TX
    3. UT MD Anderson Cancer Center, Houston, TX
    4. UT MD Anderson Cancer Center, Houston, TX
    5. UT MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author
  • Usama M,

    1. UT MD Anderson Cancer Center, Houston, TX
    2. M.D. Anderson Cancer Center, Houston, TX
    3. UT MD Anderson Cancer Center, Houston, TX
    4. UT MD Anderson Cancer Center, Houston, TX
    5. UT MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author
  • Beddar S

    1. UT MD Anderson Cancer Center, Houston, TX
    2. M.D. Anderson Cancer Center, Houston, TX
    3. UT MD Anderson Cancer Center, Houston, TX
    4. UT MD Anderson Cancer Center, Houston, TX
    5. UT MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author

Abstract

Purpose:

To evaluate the accuracy and usefulness of plastic scintillation detectors used for skin dosimetry of patients undergoing passive scatter proton therapy.

Methods:

Following an IRB approved protocol, six patients undergoing passively scattered proton beam therapy for prostate cancer were selected for in vivo skin dosimetry using the Exradin W1 plastic scintillator. The detector was calibrated on a Cobalt-60 unit, and phantom measurements in the proton beam with the W1 and a calibrated parallel plate ion chamber were used to account for the under-response due to high LET at energies used for treatment. Measurements made in a heated water tank were used to account for temperature dependence. For in vivo measurements, the W1 is fixed to the patient's skin with medical tape in the center of each of two laterally opposed treatment fields. Measurements will be performed once per week for each patient for the duration of treatment, for a total of thirty six measurements. The measured dose will be compared to the expected dose, extracted from the Eclipse treatment planning system. The average difference over all measurements and per-patient will be computed, as well as standard deviations.

Results:

The calibrated detector exhibited a 7% under-response in 225 and 250 MeV beams, and a 4% under-response when used at 37 °C (relative to the response at the calibration temperature of 20 °C). Patient measurements are ongoing.

Conclusion:

The Exradin W1 plastic scintillator detector is a strong candidate for in vivo skin dosimetry in passively scattered proton beams as PSDs are water equivalent and very small (2mm in diameter), permitting accurate measurements that do not perturb the delivered dose.

This project was supported in part by award number CA182450 from the National Cancer Institute.

Ancillary